Minerva Neurosciences reported $-6726000 in Net Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acadia Pharmaceuticals ACAD:US USD -41725000 14.54M
ALKERMES ALKS:US USD -28254000 35.72M
AstraZeneca AZN:LN USD 901M 739M
Biocryst Pharmaceuticals BCRX:US USD -71541000 29.02M
Bristol Myers Squibb BMY:US USD 2.02B 416M
Dynavax Technologies DVAX:US USD 67.73M 3.92M
Eli Lilly And LLY:US USD 1.94B 486M
Esperion Therapeutics ESPR:US USD -55487000 370K
GlaxoSmithKline GSK:LN GBP 1.5B 8.82B
Halozyme Therapeutics HALO:US USD 57.7M 3.93M
Johnson & Johnson JNJ:US USD 3.52B 938M
Marinus Pharmaceuticals MRNS:US USD -34312000 107.6M
Merk MRK:US USD 3.02B 231M
Minerva Neurosciences NERV:US USD -6726000 175K
Neurocrine Biosciences NBIX:US USD 89M 20.5M
Novartis NOVN:VX USD 1.47B 107M
Novavax NVAX:US USD -182249000 13.64M
Pfizer PFE:US USD 5B 3.61B
Roche Holding ROG:VX 3.89B 4.64B
Takeda 4502:JP JPY 119.13B 57.39B
Vanda Pharmaceuticals VNDA:US USD 6.86M 3.59M